Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Shares of Abbott Laboratories plunged 10.04% to $108.61 Thursday, on what proved to be an all-around great trading session ...

The medical-products maker’s shares tumbled after its quarterly profit and sales underwhelmed investors.

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22, as the market digested weaknesses from its fourth-quarter and full-year earnings report. | Abbott Laboratories saw ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Abbott Labs stock drops on sales miss and weak guidance for 2026, analyst cuts price target but maintains rating.

Indian drugmaker Abbott Healthcare's supply chain is being scrutinised as part of a wider investigation into the alleged ...

Despite facing headwinds, Abbott Laboratories (ABT) reports robust earnings growth and outlines plans for innovation and ...

Abbott Laboratories ( ABT) Q4 2025 Earnings Call January 22, 2026 9:00 AM EST Good morning, and thank you for standing by.

In recent weeks, Abbott Laboratories raised its quarterly dividend for the 52nd consecutive year and secured CE Mark approval ...